The Life Sciences team represented neuroscience company Cerevance in a $5 million extension of its Series A financing. The additional funding was provided by the Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia. In connection with this investment, Tetsuyuki Maruyama, Ph.D., Chief Scientific Officer of the Dementia Discovery Fund, joined the Cerevance board. With this additional investment, Cerevance has raised over $41 million in commitments of equity and non-dilutive capital since its launch in December 2016.
With locations in both Boston, Massachusetts and the United Kingdom, Cerevance is using a new technology in-licensed from the Howard Hughes Medical Institute laboratory of Nathaniel Heintz, Ph.D., at the Rockefeller University. This technology will enable the analysis of specific cell types in human brain tissue rather than relying on animal models to discover critical pathways and receptors present in vulnerable cell populations in diseases such as Alzheimer’s and Parkinson’s.
The Goodwin team for the extension financing was led by partners Laurie Burlingame and Kingsley Taft and associates Ben Piper and Gabriela Morales-Rivera.
For more details on the financing, please read the press release.